Transcriptomic Study of Cutaneous Fibroblasts in Scleroderma

ConditionScleroderma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCentre Hospitalier Universitaire Dijon

About this trial

Scleroderma is a complex connective tissue disease involving three interconnected pathophysiological axes: vascular hyperactivity and remodelling, immune system dysfunction and over-activation of fibroblasts at the origin of the fibrosis process in the skin and organs. Given that this pathology occurs preferentially in mature subjects, it is possible to suggest a potential inductive role for senescent fibroblasts, which would be responsible for activating and/or maintaining the immune response and systemic inflammation. Our hypothesis is that fibroblasts play a predominant role in the genesis and maintenance of this pathology.

Eligibility criteria

Qualifiers

Person who has given written consent

Person with systemic scleroderma

Person who has given written consent

Person undergoing plastic, cosmetic and reconstructive surgery

Disqualifiers

Person not affiliated to or not benefiting from a social security scheme

Person subject to a legal protection measure (curatorship, guardianship)

Person subject to a legal protection measure

An adult who is incapable or unable to give consent

Trial design

Treatments tested in this trial

  • Skin samples
  • Analysis of fibroblasts

Treatment groups

60 Participants
are divided into 2 treatment groups